Harbour Capital Advisors, LLC Bei Gene, Ltd. Transaction History

Harbour Capital Advisors, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 05, 2024	SELL	$158.67 - $201.58 $30,147 - $38,300	-190 Reduced 6.95%	2,545 $459,000
Q3 2023 Oct 05, 2023	SELL	$179.87 - $225.13 $31,477 - $39,397	-175 Reduced 6.01%	2,735 $491,000
Q2 2023 Jul 10, 2023	BUY	$178.3 - $266.78 $6,240 - $9,337	35 Added 1.22%	2,910 $518,000
Q4 2022 Jan 13, 2023	SELL	$125.51 - $229.3 $2,510 - $4,586	-20 Reduced 0.69%	2,875 $0
Q3 2022 Oct 19, 2022	BUY	$131.8 - $202.24 $381,561 - $585,484	2,895 New	2,895 $379,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Harbour Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Harbour Capital Advisors, LLC with notifications on news.